Why the study?
Heart failure decompensation frequently involves diminished cardiac output and peripheral hypoperfusion, creating a need for inotropes. This review aims to summarize current data on their optimal use and provide expert opinion on current and future applications.
This review highlights the ongoing need for individualized use of current inotropes and the development of safer novel agents for heart failure management.
No takes yet. Share an insight, caveat, or question.
Supports cautious individualized inotrope use in HF; leaves open whether novel agents improve outcomes.
Arfaras-Melainis et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: